Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7292779 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL26634879 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL21596987 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL18604607 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL19460948 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL6449941 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1149061 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL1041731 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL17286185 | 0.98 | TDP1 (0.71) | TDP1MEN1KMT2AGAAMAOA | |
| SCHEMBL7434 | 0.94 | TDP1 (0.65) | TDP1MEN1KMT2AGAAMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 615 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102161688-A | Cholesterol-structure-fragment-containing biocompatible synthesis liposomes as well as preparation method and application thereof | SHANGHAI INST ORGANIC CHEM | 2011-08-24 | — | — | CN | claimed |
| WO-2009064485-A1 | ANTIOXIDANT FLAVONOID DERIVATIVES | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-05-22 | — | — | WO | claimed |
| US-20260137629-A1 | Novel Lipids For Delivery Of Nucleic Acid Segments | ASTRAZENECA AB (SE) | 2026-05-21 | — | — | US | disclosed |
| WO-2026086944-A1 | AMINOPYRIDONE MACROLIDE COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2026-04-30 | — | — | WO | disclosed |
| WO-2026086945-A1 | PYRAZINE MACROLIDE COMPOUND AND USE THEREOF | 苏州信诺维医药科技股份有限公司 | 2026-04-30 | — | — | WO | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2026-04-23 | — | — | US | disclosed |
| EP-4722206-A1 | BENZO(HETERO)CYCLOALKYL COMPOUNDS FOR ANDROGEN RECEPTOR-DEPENDENT DISEASES | Haihe Biopharma Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4712964-A1 | COMPOUNDS AND FORMULATIONS USEFUL AS VACCINE ADJUVANTS | Merck Sharp & Dohme LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712979-A1 | COMPOUNDS AND ADJUVANT FORMULATIONS USEFUL IN PNEUMOCOCCAL VACCINES | Merck Sharp & Dohme LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-0984777-A4 | ARYLSUBSTITUTED PIPERAZINES USEFUL IN THE TREATEMENT OF BENIGN PROSTATIC HYPERLASIA | ORTHO MCNEIL PHARM INC (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1085879-A2 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2001007036-A1 | BICYCLIC ANTAGONISTS SELECTIVE FOR THE αvβ3 INTEGRIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-01 | — | — | WO | disclosed |
| CN-1264300-A | Aryl substituted piperazines useful for treating benign prostatic hypertrophy | ORTHO MCNELL PHARMACEUTICAL IN (US) | 2000-08-23 | — | — | CN | disclosed |
| US-6071915-A | SELECTIVELY INHIBIT BINDING TO THE ALPHA-1A ADRENERGIC RECEPTOR; N'-(ETHYL-2-(2-ISOPROPYLOXYPHENYL)PIPERAZIN-4-YL)-(1'(2-OXYPIPERIDINYL)ACETAMIDE AND DERIVATIVES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| WO-1999063932-A9 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | ADVANCED MEDICINE INC (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0984777-A1 | ARYLSUBSTITUTED PIPERAZINES USEFUL IN THE TREATEMENT OF BENIGN PROSTATIC HYPERLASIA | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1999063932-A2 | MULTIBINDING AGENTS THAT MODULATE THE 5-HT TRANSPORTER | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| WO-1998051298-A1 | ARYLSUBSTITUTED PIPERAZINES USEFUL IN THE TREATEMENT OF BENIGN PROSTATIC HYPERLASIA | ORTHO-MCNEIL PHARMACEUTICAL INC. (US) | 1998-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137629-A1 | Novel Lipids For Delivery Of Nucleic Acid Segments | LDLR, NPC1, NSUN2 | TDP1 943/4885MEN1 3805/4885KMT2A 1911/4885 |
| US-20260108618-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | TDP1 3694/4885MEN1 4679/4885KMT2A 1692/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | TDP1 1888/4885MEN1 2647/4885KMT2A 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.